Figure 3From: Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker Kaplan-Meier PFS plots of patients who have >30% or ≤30% of their CTCs with an HER2 intensity score of 3+, with or without anti-HER2 therapy. PFS was calculated from the time of the baseline blood draw. Coordinates of the dashed lines indicate median survival time.Back to article page